Zymeworks Completes $929M Theravance Biopharma Acquisition
Vancouver, British Columbia, September 23, 2026 Zymeworks Inc. has completed its previously announced acquisition of Theravance Biopharma, Inc., bringing...
zanidatamab
Advertisement
BeOne Reports New Phase 3 Survival Data for ZIIHERA
San Carlos, Calif. – August 31, 2026 BeOne Medicines announced new Phase 3 overall survival data from the HERIZON-GEA-01...
Zymeworks Wins FDA Approval for Ziihera in HER2+ GEA
VANCOUVER, British Columbia – August 25, 2026 Zymeworks Inc. announced that its partner Jazz Pharmaceuticals has received U.S. FDA...
Jazz Pharmaceuticals Gains FDA Approval for HER2+ GEA
Dublin, Ireland, August 25, 2026 Jazz Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has approved two...
BeOne Wins FDA Approval for TEVIMBRA HER2+ GEA Regimen
SAN CARLOS, Calif., August 25, 2026 BeOne Medicines Ltd. announced that the U.S. Food and Drug Administration (FDA) has...
Advertisements
BeOne Medicines Reports Positive Phase 3 HERIZON-GEA Results at ASCO 2026
CHICAGO, Illinois and SAN CARLOS, California — May 27, 2026 BeOne Medicines announced new clinical findings from the Phase...
ALX Oncology Reports Durable HER2 Breast Cancer Data
SOUTH SAN FRANCISCO, Calif., May 7, 2026 ALX Oncology announced promising new clinical findings showing that its investigational CD47...
BeOne Medicines Gains FDA Priority Review for TEVIMBRA
SAN CARLOS, CALIFORNIA, April 29, 2026 BeOne Medicines has announced that the U.S. Food and Drug Administration (FDA) has...
Advertisement
